Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 589-596

  Malaviya, Anshuman P ^a   Östör, Andrew J K ^a,b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Abatacept; Adherence; Biologic DMARD; Compliance; Preference; Rheumatoid arthritis; Self injectable; Subcutaneous administration

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; FOSTAMATINIB; INFLIXIMAB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOFACITINIB; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRITIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; MEDICATION COMPLIANCE; MOUTH ULCER; NAUSEA; PATIENT COMPLIANCE; PATIENT PREFERENCE; REVIEW; RHEUMATOID ARTHRITIS; SELF INJECTION; TREATMENT RESPONSE;

EID: 84874271973     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S23786     Document Type: Review

References (40)

1. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003. Available from: http://apps.who.int/medicinedocs/en/d/Js4883e/. Accessed 19 June, 2012.
2. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. Apr 2010;25(4):284-290.
3. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841.
4. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842-1847.
5. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
6. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160(1): 31-37.
7. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009;26(10):936-946.
8. Salt E, Frazier S. Adherence to disease-modifying antirheumatic drugs in rheumatoid arthritis in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs. 2010;29(4):260-275.
9. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30(1):44-54.
10. Park DC, Hertzog C, Leventhal H, et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc. 1999;47(2): 172-183.
11. Gispen JG, Alarcón GS, Johnson JJ, Acton RT, Barger BO, Koopman WJ. Toxicity of methotrexate in rheumatoid arthritis. J Rheumatol. 1987;14(1):74-79.
12. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32.
13. Li P, Blum MA, Von J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health. 2010;13(6):805-812.
14. Harley C, Frytak J, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9(Suppl 6):S136-S143.
15. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 2008;59: 1519-1526.
16. Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford). 2006;45(12):1575-1576.
17. Jeffery M, Stokes A, Johnson K, Anderson D, Harper B. Patient Preferences for Tumor Necrosis Factor (TNF) Antagonist. London, UK and Dallas, TX: The Research Partnership Ltd, Rheumatology Research International; 2004.
18. Berteau C, Schwarzenbach F, Donazzolo Y, et al. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence. 2010;4:379-388.
19. Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6(1):1-14.
20. Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther. 2004;6 Suppl 2:S19-S23.
21. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-876.
22. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-1123.
23. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096-1103.
24. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870-1877.
25. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54:2807-2816.
26. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69:510-516.
27. Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63(10):2854-2864.
28. Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Ann Rheum Dis. 2012;71:38-44.
29. Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71(6):857-861.
30. Nash PT, Ludivico CL, Delaet I, et al. Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous (IV) loading dose [abstract]. Arthritis Rheum. 2011;63(Suppl 10):S151.
31. Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(5 Suppl 46):S46-S56.
32. Porter S. Human immune response to recombinant human proteins. J Pharm Sci. 2001;90:1-11.
33. Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. Apr 2009;36(4):736-742.
34. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66:228-234.
35. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.
36. Hiligsmann M, Rabenda V, Gathon H-J, Ethgen O, Reginster J-Y. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010;86(3):202-210.
37. National Institute for Health and Clinical Excellence (NICE). Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis after the Failure of a TNF Inhibitor. London, UK: National Institute for Health and Clinical Excellence; Aug 2010. 73 p. (Technology appraisal guidance; no. 195).
38. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose ranging study of the oral JAK inhibitor tofacitinib (CP 690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease modifying antirheumatic drugs. Arthritis Rheum. 2012;64(3):617-629.
39. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337-345.
40. Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis. 2006;(65 Suppl 3):iii83-iii88.